VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhDView Video
VideoOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin HuitemaView Video
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Cytotoxic agents | Markus Jörger, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Correlation between nivolumab exposure and treatment outcome in NSCLC (#O1) | Sander BinsView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants (#O9) | Parth UpadhyayView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys JonesView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhDView Slideset
MRMichelle RudekPharmD, PhDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)View Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos PapachristosView Slideset
